Kornimate/medical-research-clean huggingface dataset:
intervention to collect and utilize sexual orientation and gender identity (sogi) information in hospice

Conditions: Sexual and Gender Minorities; Hospice; Alzheimer's Disease and Related Dementias

Summary: older sexual and gender minority (sgm) patients are at risk for receiving inequitable end-of-life care; those with alzheimer's disease and related dementias (adrd) are at particularly high risk. failure to collect and integrate sexual orientation and gender identity (sogi) data to identify patients' informal support systems may have adverse health consequences for sgm older adults, particularly for those dependent on informal caregivers to provide in-home support and assist with activities of daily living. the goal of this k01 is develop a novel training for hospice staff in person-centered communication that includes sogi data collection to promote authentic end-of-life care for sgm patients and their caregivers.

collecting representative and inclusive data about sexual orientation and gender identity (sogi) is a critical component of combating the devastating health disparities affecting sexual and gender minority (sgm) older adults. this is particularly crucial for patients living with adrd, which is widely regarded as a family disease requiring the active caregiver involvement, particularly with advanced disease. failure to collect and integrate sogi data to identify patients' informal support systems may have adverse health consequences for sgm older adults, particularly for those dependent on informal caregivers to provide in-home support and assist with activities of daily living. improper identification of chosen family and caregivers contributes to incomplete care delivery and disenfranchised grief. given the historical discrimination experienced by older sgm people, adding sogi questions without proper training has the potential to harm patients and create staff discomfort rather than foster inclusive interactions. for this career development award, i propose to characterize sogi data collection challenges from patients and caregivers enrolling in hospice while exploring understudied intersections, such as sgm people living with adrd, and how they affect staff approaches to delivering person-centered care. these insights will be used to develop and pilot test an intervention to train hospice interdisciplinary team (idt) staff to sensitively collect and utilize sogi data to improve communication with sgm patients and caregivers.

Eligibility criteria:
inclusion criteria: * english speaking * 18 years and above exclusion criteria: --people under 18, pregnant women, prisoners, and people who are decisionally challenged will be excluded from the study.
study of the treatment of experimental pain in buprenorphine maintained persons with chronic musculoskeletal pain

Conditions: Opioid-Related Disorders; Chronic Pain

Summary: pain is very common in persons with a history of addiction, but few studies have examined the best treatment of pain in this population. this is a study to determine the pain relief provided by intravenous hydromorphone (dilaudid) or buprenorphine given to persons maintained on stable doses of methadone or buprenorphine who have chronic musculoskeletal pain. experimental sessions will require overnight stays on a residential research unit. in these sessions, persons will be exposed to standard experimental pain techniques at baseline and then rate the relief (if any) provided by the study medication when exposed to the same techniques. persons will be asked to participate in 3 sessions, each separated by at least 7 days.


Eligibility criteria:
inclusion criteria: opioid dependence according to the mini international neuropsychiatric interview (mini) and verified by the pi; urine toxicology negative for drugs of abuse but positive for opioid maintenance agent; stable buprenorphine (12-16 mg) dose for the past 30 days; chronic musculoskeletal pain (\>3 months) as documented in medical history and physical; able and willing to perform/tolerate pain procedures; able to communicate in english. exclusion criteria: current illicit substance use at screening or during trial as verified by urine toxicology screen and/or self-report (including cannabis use); current alcohol dependence as assessed on the mini); medical or psychiatric condition known to influence quantitative sensory testing (qst) (e.g. hiv, peripheral neuropathy, current major depressive disorder, schizophrenia, raynaud's syndrome); use of prescribed or over the counter analgesic agents or psychotropic medications known to have analgesic properties for 24 hours prior to session; previous allergic reaction to hydromorphone or buprenorphine; women who are pregnant, lactating or planning to get pregnant during the course of the trial.

Keywords: quantitative sensory testing hydromorphone buprenorphine
osteopathic manipulative treatment efficacy in postoperative pain

Conditions: Surgery; Pain

Summary: effectively controlling sternal pain during cardiac rehabilitation after heart surgery is very important as it reduces the risk of postoperative complications. however, the contraindications and side effects of analgesic drugs may induce physicians to use them so cautiously that pain may actually be under-treated. the aim of this open label, controlled study is to assess whether osteopathic manipulative treatment (omt) can contribute to pain relief and improve rehabilitation outcomes.

the currently predominant means of controlling postoperative pain is the peri-operative administration of opioid or non-opioid (acetaminophen) analgesics, alone or in combination, and non-steroidal anti-inflammatory drugs (nsaids). however, anti-inflammatory drugs are contraindicated for many patients because they may impair renal function, interact with platelet aggregation, and increase the risk of gastrointestinal damage and bleeding. the spectrum of available options is narrow. osteopathic manipulative treatment (omt) intervenes in the process that transforms nociceptive information into the subjective experience and it may be useful. it has been found to be effective in controlling pain after abdominal surgery, it has a beneficial effect on patients recovering coronary artery by-pass surgery and also improves cardiac function the aim of this study was to assess whether complementary omt is an effective means of reducing post-surgical sternal pain and improving rib cage mobility after heart surgery involving sternotomy, and to investigate its advantages during in-patient rehabilitation in terms of functional recovery, and perceived anxiety and depression. this open, randomised, semi-blinded, controlled trial involves inclusion of 80 adult patients of both genders consecutively admitted as in-patients to cardiac rehabilitation unit after undergoing elective coronary artery by-pass grafting (cabg), valve replacement or repair and/or ascending aorta surgery with sternotomy, and capable of voluntarily providing their written informed consent. the patients are divided in 2 groups, the intervention group receiving omt and the control group. both groups are following the same rehabilitation programme and receiving usual care. all of the subjects taking part in the study are receiving standard care in accordance with the international guidelines for in-patient cardiac rehabilitation; the only experimental intervention is the addition of omt

Eligibility criteria:
inclusion criteria: * recent artery bypass grafting (cabg) * recent valve replacement or repair * recent ascending aorta surgery exclusion criteria: * heart surgery using mini-thoracotomy. * heart transplantation * implant of a ventricular assistance device * diabetes mellitus * rheumatoid arthritis * autoimmune diseases * altered cognitive capacities

Keywords: surgery outcome pain osteopathic manipulative treatment
improving medication adherence in comorbid conditions

Conditions: Diabetes Mellitus, Type 2; Hypertension; Hyperlipidemia

Summary: this study is designed to study how adults with type 2 diabetes and either high blood pressure and/or high blood cholesterol manage their treatment regimen. it is also called the diabetes management study. individuals need to be 40 years of age or older and on oral medication (pills) management for two of the three conditions of interest. they may also be on other treatment such as insulin, diet and/or exercise programs. individuals will be followed for approximately 12 months. about 1/4 of the persons in the study will receive a telephone counseling program with a nurse focused upon their management of their treatment program.


Eligibility criteria:
* type 2 diabetes mellitus, hypertension and/or hyperlipidemia, * on oral medication for two of the above conditions, * manage own medications, * must have access to a telephone, * not participating in other adherence education or counseling trials

Keywords: diabetes
prospective, non-interventional, multi-center post-authorization safety study of riociguat for chronic thromboembolic pulmonary hypertension (cteph )

Conditions: Hypertension, Pulmonary

Summary: this local, prospective, non-interventional, multi-center study includes patients treated with riociguat for inoperable cteph(chronic thromboembolic pulmonary hypertension)/ persistent or recurrent cteph after surgical treatment. it is planned to include a total of 400 patients (valid for safety analysis). this study is performed as an all-case investigation. the treatment of riociguat is performed based on the product label in japan. the standard observation period is 12 months from the 1st treatment of riociguat. safety and effectiveness are evaluated at 4th and 12th month. in addition, the extension observation is carried out once a year for 7 years at the longest to collect information on safety and effectiveness as long as riociguat treatment continues. when the treatment of riociguat is terminated, observation of a patient ends. for each patient, the investigator records data as defined in the protocol at each evaluation point by using the electronic data capture (edc) system. the duration of the study is approximately 9 years from launch.


Eligibility criteria:
inclusion criteria: * patients who are treated with riociguat for cteph exclusion criteria: * patients who are contraindicated based on the product label

Keywords: riociguat, adempas, sgc stimulator, cteph, japan, pms
assessment of the association between visceral obesity and the progression of diabetic nephropathy

Conditions: Diabetic Nephropathies

Summary: assessment of the association between visceral obesity and the progression of diabetic nephropathy

type 2 diabetes mellitus is a disorder of diverse aetiology characterised by hyperglycemia resulting from abnormalities of insulin action, insulin production, or both, and the global population with diabetes mellitus is expected to be around 439 million by 2030 . diabetic nephropathy is the most prevalent microvascular consequence of dm. it develops in around 40% of dm patients. obesity, which has now reached pandemic ratios, is frequently accompanied by diabetes mellitus type 2 because they share common pathophysiological pathways . abdominal obesity is found to be a negligent form of obesity with dangerous consequences. it has been identified as potentially hazardous factor for diabetic complications. several abdominal obesity measures have been developed including the visceral adiposity index (vai) , lipid accumulation product (lap) , neck circumference (nc), waist-to-hip ratio (whr) lipid accumulation product (lap) and visceral adiposity index (vai) are new, non-imaging indicators of visceral adiposity measured using body mass index (bmi), waist circumference (wc), and serum lipid profile. it was predicted in some studies that lap and vai have a stronger association with poor renal outcomes than bmi and wc.

Eligibility criteria:
inclusion criteria: - 1. diabetic patients either type 1 or type 2 diabetes aged \> 18 years whether known to have diabetic nephropathy or not. 2. bmi is ≥ 25 kg/m2 exclusion criteria: * 1. patients age \< 18 years. 2. bmi \< 25 kg/m2 3. nondiabetic patients 4. patients with non-diabetic kidney disease. 5. patients with aki 6. patients with ckd stage 5 either on dialysis or not.
treatment of compound tibia fracture with a microvascular latissimus dorsi flap and the ilizarov technique

Conditions: Reconstructive Surgical Procedure

Summary: this study assesses the long-term results of compound tibial reconstruction treated with a microvascular latissimus dorsi flap and bone transport technique during the last 25 year in helsinki university central hospital.

a retrospective review of hospital records was conducted to chart the clinical and operational characteristics of patient. patients current condition is assessed by applying two function-related (disabilities of the arm, hand and shoulder, dash; lower extremity functional scale, lefs) and a health-related quality of life (the 15-dimensions, 15d) questionnaires. the patients received the questionnaires by mail. a written informed consent was obtained from the participants. the obtained data was computerized and analyzed.

Eligibility criteria:
inclusion criteria: * age over 15 years. * patients with acute compound tibial fracture or sequela treated with free latissimus dorsi flap and bone transport. exclusion criteria: * deceased. * patients under 15 years of age.

Keywords: latissimus dorsi flap bone transport bone reconstruction tibia tibial fracture
evaluation of the effectiveness of non-invasive ventilation on the reperfusion pulmonary edema post pulmonary artery angioplasty in the post embolic pulmonary hypertension

Conditions: Reperfusion Pulmonary Edema

Summary: the purpose of this study is to determine whether non invasive ventilation are effective in prevention of reperfusion pulmonary edema after pulmonary artery angioplasty. our hypothesis is that administration of non invasive ventilation during the procedure and systematically in post procedure period is a protective factor against the development and severity of reperfusion pulmonary edema.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * first and /or second procedure of pulmonary artery angioplasty * mean pulmonary arterial pressure ≥ 40 mmhg and/or pulmonary vascular resistance ≥ 8 wu (wood unit) * patient who signed informed consent * patients affiliated to a social security program exclusion criteria: * severe neurological disease: coma glasgow scale \< 8, severe cognitive decline, postural instability, loss of autonomy. * psychiatric disease (illness) * sepsis, severe sepsis and septic shock, according to definitions and diagnostic criteria for sepsis of 'surviving sepsis campaign 2012' * severe respiratory failure defined by a total lung capacity (tlc)\< 50% of the predicted value and/or expiratory volume in 1 second (fev) \< 30% of predicted value * obstructive sleep apnea syndrome with continuous positive airway treatment * preexisting hemorrhagic syndrome or coagulation factors deficiency * severe renal insufficiency with glomerular filtration rate \< 30 ml/min * severe hepatic failure with hepatic encephalopathy, hemodynamic disorder, decompensates cirrhosis, metabolic disorder( metabolic acidosis, hypoglycemia) hepatorenal syndrome, coagulation disorder (factor v\< 50%,disseminated intravascular coagulation) * patient refusal of participation in the study program * subjects not affiliated to social security program

Keywords: non invasive ventilation reperfusion pulmonary edema chronic thrombolic pulmonary hypertension pulmonary artery angioplasty
hypoxia at multiple wavelengths of light

Conditions: Hypoxia in Healthy Individuals

Summary: the purpose of the study is to assess the effect of progressive, incremental hypoxia at multiple wavelengths of light.

no additional information is required.

Eligibility criteria:
inclusion criteria: * is between 18 and 35 years of age * is american society anesthesiologist status 1 * has a bmi between 18 and 30 exclusion criteria: * currently taking any medications other than birth control pills * has participate in an investigational drug study within one month prior to the start of the study * fails the allen's test to confirm patency of the colateral artery * subject is female with a positive pregnancy test, or is female and is unwilling to use effective birth control between the time of screening and study termination * has a positive urine continine or drug test * has an reported allergy to lidocaine * has anemia or other hemoglobinopathy * has a room air saturation less than 95% by pulse oximetry * has an abnormal ekg * has an abnormal pulmonary function test via spirometry * is intolerant to a breathing mask apparatus * has a cohb greater than 3%, or methb greater than 2% * has another condition, which in the opinion of the principle investigator would not be suitable for participation in the study * is unwilling or unable to provide informed consent or comply with the study procedures

Keywords: hypoxia multiple wavelengths
mobile app for obsessive-compulsive disorder in adolescents

Conditions: Obsessive-Compulsive Disorder in Adolescence

Summary: the aim of the present study is to assess the efficacy of the module ggoc-ad (gg obsessive-compulsive disorder - adolescents) in reducing obsessive-compulsive disorder (ocd) related maladaptive beliefs and ocd symptoms in adolescents from 15 to 18 years old. specifically, a randomized controlled trial with two conditions (experimental and control) will be carried out in a non-clinical adolescent population to assess pre-post-intervention changes. after 14 days of using ggoc-ad, it is expected, primarily, to find a decrease in ocd-related maladaptive beliefs and ocd symptoms. as secondary results, we do not expect changes in emotional symptomatology, but we do expect an increase in self-esteem. additionally, these changes are expected to be found in a one-month follow-up.

pediatric ocd is a serious problem and, if not treated early on, is associated with significant impairment. the app ggoc, aimed at working on ocd-related dysfunctional beliefs in adults, has proven in previous studies in adult clinical and non-clinical samples, to significantly decrease maladaptive beliefs associated with ocd and obsessive-compulsive symptomatology. also, it can significantly increase self-esteem. therefore, it is relevant to adapt the ggoc application to the adolescent population (ggoc-ad) and evaluate its effectiveness.

Eligibility criteria:
inclusion criteria: 1. to have signed the informed consent, both the adolescents and their parents or legal guardians. 2. being enrolled in 4th level of obligatory secondary education of the spanish education system (isced levels 2 and 3 in the international standard classification of education) 3. to have a mobile phone (indistinctly android or ios mobile system) with internet access.

Keywords: obsessive-compulsive disorder cognitive therapy maladaptive beliefs mobile app adolescence
organ protective effect of cetirizine in patients with severe burns

Conditions: Burns

Summary: this prospective clinical trial aims to investigate the organ protective effects of cetirizine in patients with severe burns.

this is a prospective, randomized, single-blind, parallel-controlled clinical trial. the global objective is to compare the organ protective effects of the sedation and analgesia regimen (midazolam, fentanyl) with the modified sedation and analgesia regimen (midazolam, fentanyl, cetirizine) in patients with severe burns (≥30% tbsa). participants will receive the intervention from admission to 72 hours post-burn. researchers will take the apache ii scores on days 7 after admission as the main outcomes. researchers will also take other supplementary examination results into account, including liver enzyme, myocardial enzyme, renal function, haemodynamic index, coagulation function, and pulmonary interstitial edema.

Eligibility criteria:
inclusion criteria: * signed and dated informed consent form * commitment to comply with the procedures and cooperation during the course * tbsa \>30% and admitted within the first day after burns * no severe compound injuries exclusion criteria: * history of allergy to drugs in the trial * postoperative complications that would interfere with the observation * mental illness and severe heart disease, hypertension * serious genetic diseases * incomplete clinical information (unclear diagnosis, incomplete medical history, incomplete medication records, etc.) * pregnancy/lactation * malignant tumors * organ insufficiency due to previous chronic diseases such as hypertension, diabetes mellitus or non-burning factors * serious adverse reactions * self-requested withdrawal
early vascular ageing among cypriots

Conditions: Vascular Stiffness; Obesity

Summary: the lifeeva project aims to tackle the significant public health challenge of cardiovascular disease (cvd) by addressing early vascular ageing (eva), characterized by increased arterial stiffness and reduced vascular compliance, particularly in young adults. the project seeks to develop and implement innovative, personalized lifestyle interventions targeting cypriots aged 18-40 who are overweight or obese. utilizing genetic data from biobank.cy, lifeeva aims to understand the progression of eva and reduce cvd risk through tailored dietary and physical activity counseling. the methodology involves a prospective, randomized, open-label, blinded endpoint trial over one year. participants will be recruited from biobank.cy's database, ensuring a robust sample. they will receive personalized interventions based on their genetic profile, including a hypocaloric diet, physical activity plan and taking into account other factors (i.e. sleep, anxiety etc). the project's work is divided into five work packages: project management, dissemination and exploitation activities, baseline assessment and recruitment, intervention implementation and data collection, and data analysis and manuscript preparation. anticipated results include significant reductions in vascular stiffness, improved cardiovascular health markers, and enhanced understanding of the interplay between genetics and lifestyle in eva. the project's impact extends to the establishment of a vascular health assessment clinic, contributions to public health by reducing cvd prevalence, and advancing the field of personalized preventive healthcare. lifeeva is positioned to make significant contributions to cardiovascular research, promote innovation, and enhance the scientific and public health landscape in cyprus.


Eligibility criteria:
inclusion criteria: * 18 - 40 years old. * bmi≥25 kg/m². * wc≥0.9 m for men and ≥0.8 m for women exclusion criteria: * individuals with a history of eating disorders. * those with significant chronic diseases like advanced cardiovascular diseases * pregnant or breastfeeding women or women to intend/are in the process of trying to get pregnant within 1-year after intervention onset. * individuals currently on medication or diets that significantly affect metabolism or body weight. * those who have participated in another weight loss program or study within the last six months. * taking any vasoactive medications.